The data on Pfizer's GLP-1 offer early evidence that the injection can be administered less frequently than existing drugs ...
By Michael Erman and Mrinalika Roy Feb 3 (Reuters) - Pfizer on Tuesday released trial data on a high-profile obesity drug ...
Pfizer (NYSE:PFE) reported positive Phase 2b VESPER-3 data for its monthly injectable GLP-1 obesity therapy acquired from ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results